HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment

Oncologist

Volumn 14, Issue 8, 2009, Pages 760-768

  Barron, John J ^a   Cziraky, Mark J ^a   Weisman, Thomas ^b   Hicks, David G ^c  

^a HEALTHCORE INC   (United States)

^b American Imaging Management   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Guideline adherence; Human epidermal growth factor receptor 2; Managed care; Trastuzumab

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ETOPOSIDE; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GEMCITABINE; LETROZOLE; METHOTREXATE; NAVELBINE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; FEMALE; HEALTH CARE PLANNING; HUMAN; MAJOR CLINICAL STUDY; MANAGED CARE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GUIDELINE ADHERENCE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 70249145878     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0288     Document Type: Article

References (45)

1. Chassin MR, Galvin RW. The urgent need to improve health care quality. Institute of Medicine National Roundtable on Health Care Quality. JAMA 1998;280:1000-1005.
2. National Committee for Quality Assurance (NCQA). HEDIS 2006. Healthcare Effectiveness Data & Information Set. Vol 2. Technical Specifications; 2005.
3. Wennberg JE. Practice variation: implications for our health care system. Manag Care 2004;13:3-7.
4. Agency for Healthcare Research and Quality. Evidence-based practice centers: synthesizing scientific evidence to improve quality and effectiveness in health care; 2007. Available at: http://www.ahrq.gov/clinic/epc, accessed November 3, 2008.
5. Chassin MR. Practice guidelines: best hope for quality improvement in the 1990s. J Occup Med 1990;32:1199-1206.
6. Farquhar CM, Kofa EW, Slutsky JR. Clinicians' attitudes to clinical practice guidelines: a systematic review. Med J Aust 2002;177:502-506. (Pubitemid 35378642)
7. Kanouse DE, Winkler JD, Kosecoff J et al. Changing medical practice through technology assessment: an evaluation of the NIH Consensus Development Program. RAND Corporation; 1989.
8. Lomas J, Anderson GM, Domnick-Pierre K et al. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med 1989;321:1306-1311. (Pubitemid 19267218)
9. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145. (Pubitemid 350003059)
10. National Committee for Quality Assurance (NCQA). The State of Health Care Quality 2007. Available at: http://www.ncqa.org/Portals/0/ Publications/ Resource%20Library/SOHC/SOHC-07.pdf, accessed January 8, 2008.
11. Bast RC Jr, Ravdin P, Hayes DF et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-1878. (Pubitemid 32230890)
12. Carlson RW, Moench SJ, Hammond ME et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006;4(suppl 3):S1-S22.
13. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer v. 2 2008. Available at: http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf, accessed December 21, 2007.
14. Austoker J. The potential and pitfalls for developing guidelines in oncology. Ann Oncol 2001;12:1189-1190. (Pubitemid 32994739)
15. Balasubramanian SP, Murrow S, Holt S et al. Audit of compliance to adjuvant chemotherapy and radiotherapy guidelines in breast cancer in a cancer network. Breast 2003;12:136-141. (Pubitemid 36546438)
16. Bickell NA, McEvoy MD. Physicians' reasons for failing to deliver effective breast cancer care: a framework for underuse. Med Care 2003;41:442-446.
17. Bloom BS, de Pouvourville N, Chhatre S et al. Breast cancer treatment in clinical practice compared to best evidence and practice guidelines. Br J Cancer 2004;90:26-30. (Pubitemid 38174933)
18. Hébert-Croteau N, Brisson J, Latreille J et al. Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol 2004;22: 3685-3693. (Pubitemid 41095207)
19. Landercasper J, Dietrich LL, Johnson JM. A breast center review of compliance with National Comprehensive Cancer Network Breast Cancer guidelines. Am J Surg 2006;192:525-527. (Pubitemid 44344204)
20. White V, Pruden M, Giles G et al. The management of early breast carcinoma before and after the introduction of clinical practice guidelines. Cancer 2004;101:476-485. (Pubitemid 38970598)
21. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004;5:63-69.
22. Yaziji H, Goldstein LC, Barry TS et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004;291:1972-1977. (Pubitemid 38544278)
23. Pengram MD, Konecny G, Slamon DJ. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of Herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 2000;103:57-75.
24. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
25. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-712. (Pubitemid 19147683)
26. Hicks DG, Kulkarni S. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol 2008;129:263-273. (Pubitemid 352029317)
27. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353: 1673-1684. (Pubitemid 41464706)
28. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792. (Pubitemid 32222155)
29. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672. (Pubitemid 41464705)
30. Culliton BJ. Insurers And 'Targeted Biologics' For Cancer: A Conversation With Lee N. Newcomer. Health Affairs-Web Exclusives 27[1], w41-w51. 11-27-10007
31. Newcomer L. How one payer has stimulated a change in ESA therapy. Community Oncol 2007;4:393. (Pubitemid 46974062)
32. Stern D, Reissman D. Specialty pharmacy cost management strategies of private health care payers. J Manag Care Pharm 2006;12(9):736-744. (Pubitemid 47398731)
33. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Available at: http://www.cdc.gov/nchs/about/otheract/ icd9/abticd9.htm, accessed December 3, 2007.
34. Paik S, Bryant J, Tan-Chiu E et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-854. (Pubitemid 34705057)
35. Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005;94:S5a.
36. Burgers JS, Fervers B, Haugh M et al. International assessment of the quality of clinical practice guidelines in oncology using the Appraisal of Guidelines and Research and Evaluation Instrument. J Clin Oncol 2004;22:2000-2007. (Pubitemid 41095193)
37. Fervers B, Burgers JS, Haugh MC et al. Predictors of high quality clinical practice guidelines: examples in oncology. Int J Qual Health Care 2005;17: 123-132. (Pubitemid 40485639)
38. Cabana MD, Rand CS, Powe NR et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;282: 1458-1465.
39. Grilli R, Magrini N, Penna A et al. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet 2000;355:103-106. (Pubitemid 30068554)
40. Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA 1999;281:1900-1905. (Pubitemid 29242803)
41. Dendukuri N, Khetani K, McIsaac M et al. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ 2007;176:1429-1434. (Pubitemid 46762020)
42. Cell Markers and Cytogenetics Committees, College of American Pathologists. Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med 2002;126:803-808.
43. Reddy JC, Reimann JD, Anderson SM et al. Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer 2006;7:153-157.
44. Roche PC, Suman VJ, Jenkins RB et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94:855-857.
45. Perez EA, Suman VJ, Davidson NE et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006;24:3032-3038.